Colin Begg | Academic Influence

Colin Begg 's AcademicInfluence.com Rankings

Colin Begg

Mathematics

#4217

World Rank

#6038

Historical Rank

Statistics

#210

World Rank

#263

Historical Rank

Measure Theory

#318

World Rank

#483

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Colin Begg 's Degrees

Bachelors Mathematics University of Aberdeen

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Colin Begg Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Colin B. Begg is a Scottish biostatistician and epidemiologist. He is an attending biostatistician at the Memorial Sloan-Kettering Cancer Center in New York City. He serves as editor-in-chief of the journal Clinical Trials. He has conducted research on the role of BRCA genetic variants in the development of breast cancer, as well as racial disparities in cancer survival rates in the United States.

(See a Problem?)

Colin Begg 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Operating characteristics of a rank correlation test for publication bias. (1994) (13596)
Improving the quality of reporting of randomized controlled trials. The CONSORT statement. (1996) (3429)
Prognostic effect of weight loss prior tochemotherapy in cancer patients (1980) (2049)
Impact of hospital volume on operative mortality for major cancer surgery. (1998) (1599)
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. (1980) (951)
Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985) (862)
Publication bias : a problem in interpreting medical data (1988) (756)
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. (1999) (729)
Assessment of diagnostic tests when disease verification is subject to selection bias. (1983) (692)
The influence of hospital volume on survival after resection for lung cancer. (2001) (678)
Racial differences in the treatment of early-stage lung cancer. (1999) (577)
Variations in lung cancer risk among smokers. (2003) (560)
Variations in morbidity after radical prostatectomy. (2002) (542)
Biases in the assessment of diagnostic tests. (1987) (514)
Age and adjuvant chemotherapy use after surgery for stage III colon cancer. (2001) (510)
Influence of hospital procedure volume on outcomes following surgery for colon cancer. (2000) (486)
Computed tomography screening and lung cancer outcomes. (2007) (463)
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. (1991) (448)
Prognostic factors in differentiated carcinoma of the thyroid gland. (1992) (401)
Survival of blacks and whites after a cancer diagnosis. (2002) (394)
Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection (2002) (342)
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. (2003) (337)
The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes (2003) (315)
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. (2006) (301)
Variation of breast cancer risk among BRCA1/2 carriers. (2008) (271)
Clinical trials and drug toxicity in the elderly. The experience of the eastern cooperative oncology group (1983) (264)
A General Regression Methodology for ROC Curve Estimation (1988) (263)
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. (1999) (257)
Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. (1996) (251)
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection (2003) (247)
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. (2002) (242)
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. (2003) (241)
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. (2001) (234)
Statistical analysis of molecular epidemiology studies employing case-series. (1994) (229)
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. (2004) (228)
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. (2013) (221)
On the use of familial aggregation in population-based case probands for calculating penetrance. (2002) (218)
Breast cancer after chest radiation therapy for childhood cancer. (2014) (210)
A distribution-free procedure for comparing receiver operating characteristic curves from a paired experiment (1996) (210)
A treatment allocation procedure for sequential clinical trials. (1980) (209)
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. (2005) (209)
Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma (2007) (206)
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. (2005) (204)
Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas (1994) (194)
Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. (1994) (189)
An Approach for Assessing Publication Bias Prior to Performing a Meta-Analysis (1992) (184)
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. (1989) (177)
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. (2010) (167)
Physician visits prior to treatment for clinically localized prostate cancer. (2010) (164)
One statistical test is sufficient for assessing new predictive markers (2011) (162)
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. (2001) (155)
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. (2015) (152)
A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. (1984) (145)
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. (1984) (145)
Two‐Stage Designs for Gene–Disease Association Studies with Sample Size Constraints (2004) (142)
Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers (2009) (137)
CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. (1997) (136)
Two‐Stage Designs for Gene–Disease Association Studies (2002) (136)
Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. (2014) (134)
Treatment allocation methods in clinical trials: a review. (1985) (134)
Adherence to surveillance among patients with superficial bladder cancer. (2003) (133)
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999 (2005) (133)
The association of patients' socioeconomic characteristics with the length of hospital stay and hospital charges within diagnosis-related groups. (1988) (132)
The effect of age on the care of women with breast cancer in community hospitals. (1987) (132)
An Assessment of Publication Bias Using a Sample of Published Clinical Trials (1989) (126)
High-dose ifosfamide with mesna uroprotection: a phase I study. (1990) (126)
Advances in statistical methodology for diagnostic medicine in the 1980's. (1991) (123)
ALCOHOL CONSUMPTION AND BREAST CANCER (1983) (116)
Measuring Complications of Cancer Treatment Using the SEER-Medicare Data (2002) (113)
Construction of Receiver Operating Characteristic Curves when Disease Verification Is Subject to Selection Bias (1984) (113)
Ambient UV, personal sun exposure and risk of multiple primary melanomas (2007) (113)
Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. (1995) (110)
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study (2010) (109)
The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study (2006) (109)
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. (2006) (105)
Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. (2006) (105)
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. (2013) (102)
Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. (1980) (101)
On the use of surrogate end points in randomized trials (2000) (100)
Assessment of Diagnostic Technologies: Methodology for Unbiased Estimation from Samples of Selectively Verified Patients (1985) (100)
The use of ambulatory testing in prepaid and fee-for-service group practices. Relation to perceived profitability. (1986) (93)
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency (2016) (93)
Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. (2000) (93)
Rare germline mutations in PALB2 and breast cancer risk: A population‐based study (2012) (92)
A measure to aid in the interpretation of published clinical trials. (1985) (91)
Attribution of deaths following cancer treatment. (2002) (88)
Sun protection and skin self‐examination in melanoma survivors (2009) (87)
Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. (2005) (86)
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. (2008) (81)
Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival. (1981) (81)
impact of Hospital Volume on Operative Mortality for Major Cancer Surgery (1999) (81)
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. (1997) (80)
Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group. (1982) (77)
Comparing ROC curves derived from regression models (2013) (76)
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. (2006) (75)
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. (2013) (73)
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer (2010) (73)
The influence of uninterpretability on the assessment of diagnostic tests. (1986) (72)
An efficient basket trial design (2017) (68)
On inferences from Wei's biased coin design for clinical trials (1990) (65)
Random Effects Models for Combining Results from Controlled and Uncontrolled Studies in a Meta-Analysis (1994) (63)
Reporting Participation in Case-Control Studies (2002) (63)
CDKN2A germline mutations in individuals with cutaneous malignant melanoma. (2007) (62)
Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. (1978) (62)
Vitamin D receptor polymorphisms in patients with cutaneous melanoma (2012) (61)
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. (2008) (60)
An assessment of estimation methods for generalized linear mixed models with binary outcomes (2013) (58)
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. (2002) (57)
A model for incorporating historical controls into a meta-analysis. (1991) (56)
Properties of analysis methods that account for clustering in volume–outcome studies when the primary predictor is cluster size (2007) (52)
Eligibility and extrapolation in cancer clinical trials. (1987) (51)
Optimal sample size for a series of pilot trials of new agents. (1996) (50)
The effects of physicians' training and personality on test ordering for ambulatory patients. (1984) (50)
Benchmarking lung cancer mortality rates in current and former smokers. (2004) (49)
Associations of Cumulative Sun Exposure and Phenotypic Characteristics with Histologic Solar Elastosis (2010) (49)
A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data (2010) (49)
A note on the estimation of relative risks of rare genetic susceptibility markers. (1997) (49)
Statistical diagnosis when basic cases are not classified with certainty (1976) (49)
Methodology for the Differential Diagnosis of a Complex Data Set (1983) (49)
Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. (1987) (49)
Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas (2012) (48)
Cooperative groups and community hospitals. Measurement of impact in the community hospitals (1983) (48)
Suspended judgment. Significance tests of covariate imbalance in clinical trials. (1990) (47)
Cancer chemotherapy in the elderly. (1989) (46)
Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. (2009) (46)
Testing for Fetal Pulmonary Maturity (1990) (46)
Proceedings of the second international molecular pathological epidemiology (MPE) meeting (2015) (45)
A comparative clinical trial of adriamycin and 5‐fluorouracil in advanced prostatic cancer: Prognostic factors and response (1983) (45)
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. (2008) (44)
The search for cancer risk factors: when can we stop looking? (2001) (44)
The comparison of total body irradiation vs chlorambucil and prednisone for remission induction of active chronic lymphocytic leukemia: an ECOG study. Part I: total body irradiation-response and toxicity. (1981) (43)
The impact of treatment allocation procedures on nominal significance levels and bias. (1987) (43)
EDITORIALS Reflections on the Landmark Studies of -Carotene Supplementation (2004) (42)
Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions (2012) (42)
Treatment allocation for nonlinear models in clinical trials: the logistic model. (1984) (42)
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. (2012) (40)
Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles (2011) (39)
High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. (1988) (39)
High-dose thiotepa alone and in combination regimens with bone marrow support. (1990) (38)
MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors (2014) (36)
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. (1997) (35)
A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia. (1984) (35)
Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. (2010) (34)
ROC curve regression analysis: the use of ordinal regression models for diagnostic test assessment. (1994) (34)
Inherited Genetic Variants Associated with Occurrence of Multiple Primary Melanoma (2015) (34)
Statistical Tests for Clonality (2007) (33)
Contralateral breast cancers: Independent cancers or metastases? (2018) (32)
Ruminations on the intent-to-treat principle. (2000) (30)
Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. (2009) (30)
Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. (2016) (30)
Familial aggregation of melanoma risks in a large population-based sample of melanoma cases (2004) (30)
A comparison of methods to detect publication bias in meta‐analysis by P. Macaskill, S. D. Walter and L. Irwig, Statistics in Medicine, 2001; 20:641–654 (2002) (30)
Clonal relationships between lobular carcinoma in situ and other breast malignancies (2016) (30)
A conceptual and methodological framework for investigating etiologic heterogeneity (2013) (30)
Patient-Oriented Performance Measures of Diagnostic Tests (1984) (30)
Reproductive History and Risk of Second Primary Breast Cancer: The WECARE Study (2007) (30)
Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. (2011) (29)
On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) (2000) (29)
Pharmacokinetics of continuous-infusion high-dose thiotepa. (1987) (27)
Sun Exposure and Melanoma Survival: A GEM Study (2014) (27)
Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways. (2016) (26)
The Prevalence of CDKN 2 A GermLine Mutations and Relative Risk for Cutaneous Malignant Melanoma : An International Population-Based Study (2006) (26)
Consensus Diagnoses and "Gold Standards" (1990) (26)
Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity. (2016) (26)
Taking stock of volume-outcome studies. (2003) (25)
Inherited variation at MC1R and ASIP and association with melanoma‐specific survival (2015) (25)
The effects of group size on test ordering for hypertensive patients. (1983) (25)
HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case–control analyses (2005) (25)
Human hypervariable sequences in risk assessment: rare Ha-ras alleles in cancer patients. (1987) (24)
The use of hierarchical models for estimating relative risks of individual genetic variants: An application to a study of melanoma (2008) (24)
Estimating the empirical Lorenz curve and Gini coefficient in the presence of error with nested data (2008) (24)
Statistical methods in medical diagnosis. (1986) (24)
Cautionary Note on Using Cross-Validation for Molecular Classification. (2016) (23)
A strategy for distinguishing optimal cancer subtypes (2011) (23)
The impact of malnutrition on treatment results in breast cancer. (1981) (23)
Systematic reviews of diagnostic accuracy studies require study by study examination: first for heterogeneity, and then for sources of heterogeneity. (2005) (23)
Reflections on the landmark studies of beta-carotene supplementation. (2004) (23)
Familial aggregation of melanoma risks in a large population-based sample of melanoma cases (2004) (23)
USING SOMATIC MUTATION DATA TO TEST TUMORS FOR CLONAL RELATEDNESS. (2015) (23)
Detecting and exploiting etiologic heterogeneity in epidemiologic studies. (2012) (22)
Hierarchical Modeling for Estimating Relative Risks of Rare Genetic Variants: Properties of the Pseudo‐Likelihood Method (2011) (22)
Methodology for case-control studies with prevalent cases (1987) (21)
Surface marker identification of small cleaved follicular center cell lymphomas with a highly favorable prognosis. (1982) (21)
Inherited Variation at MC1R and Histological Characteristics of Primary Melanoma (2015) (21)
A study of the use of the probability-of-being-in-response function as a summary of tumor response data. (1982) (21)
Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: A population-based study. (2015) (21)
Sequential analysis of comparative clinical trials (1979) (20)
A risk prediction model for the development of subsequent primary melanoma in a population‐based cohort (2020) (20)
Variants in autophagy‐related genes and clinical characteristics in melanoma: a population‐based study (2016) (20)
Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma (2017) (19)
Selection of patients for clinical trials. (1988) (19)
Evaluating Cancer Epidemiologic Risk Factors Using Multiple Primary Malignancies (2010) (18)
Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA 1 or BRCA 2 (2010) (18)
Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer. (1994) (18)
Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies? (2005) (18)
Bone marrow transplantation versus chemotherapy in acute non-lymphocytic leukemia: a meta-analytic review. (1989) (18)
Experimental design of medical imaging trials. Issues and options. (1989) (18)
Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. (1981) (17)
Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge (2010) (17)
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474). (1979) (17)
Timing of radiotherapy in the treatment of early-stage breast cancer. (1993) (17)
Blocking and Randomization to Improve Molecular Biomarker Discovery (2014) (17)
Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling (2011) (16)
Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. (1981) (16)
Variation of Breast Cancer Risk Among BRCA 1 / 2 Carriers : An Investigation by the WECARE Study Group (2009) (16)
Patient-Oriented Performance Measures of Diagnostic Tests (1984) (16)
Kin‐cohort evaluation of relative risks of genetic variants (2003) (16)
Marrow transplantation for acute nonlymphoblastic leukemia. (1980) (16)
Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer (2015) (16)
State of the art in comparative cancer clinical trials (1987) (16)
Reflections on Publication Criteria for Genetic Association Studies (2005) (15)
Genomic investigation of etiologic heterogeneity: methodologic challenges (2014) (15)
A comparison of statistical methods for the study of etiologic heterogeneity (2017) (15)
Proceedings of the third international molecular pathological epidemiology (MPE) meeting (2016) (15)
MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study (2010) (15)
Functional melanoma‐risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas (2017) (15)
Comparison of Properties of Tests for Assessing Tumor Clonality (2008) (15)
Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study (2010) (14)
Statistics in Medical Research: Developments in Clinical Trials (1996) (14)
The role of meta-analysis in monitoring clinical trials. (1996) (14)
The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival (2018) (14)
Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints (1999) (13)
Using somatic variant richness to mine signals from rare variants in the cancer genome (2019) (13)
Meta-analysis methods for diagnostic accuracy. (2008) (13)
A New Strategy for Evaluating the Impact of Epidemiologic Risk Factors for Cancer with Application to Melanoma (1998) (13)
Ethical concerns about adaptive randomization (2015) (12)
Multiple imputation for correcting verification bias by Ofer Harel and Xiao‐Hua Zhou, Statistics in Medicine 2006; 25:3769–3786 (2007) (12)
The mammography controversy. (2002) (11)
Evaluation of bone marrow toxic reaction in patients treated with allopurinol. (1982) (11)
There is still a place for significance testing in clinical trials (2019) (11)
Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study. (1993) (11)
Chemotherapy for advanced germinal cell neoplasms: preliminary report of an Eastern Cooperative Oncology Group Study. (1979) (11)
New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. (2012) (10)
Specifying the True- and False-Positive Rates in Basket Trials. (2017) (10)
MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. (2019) (10)
“Right to Try” laws (2014) (10)
Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma. (2017) (10)
Estimating the relative risk of developing melanoma in INK4A carriers (2004) (9)
Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. (2018) (9)
Diamond's Correction Method-A Real Gem or Just Cubic Zirconium? (1991) (9)
Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries (2017) (9)
Response to ROC Steady (1987) (8)
Estimating the probability of clonal relatedness of pairs of tumors in cancer patients (2018) (8)
[Improving the quality of reports on randomized controlled trials. Recommendations of the CONSORT Study Group]. (1998) (8)
Methodologic standards for diagnostic test assessment studies (1988) (8)
Letter to the Editor of Biometrics (2007) (8)
Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. (2008) (8)
Erratum: Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas (ann surg oncol (2012) 19 (1024-1033) DOI: 10.1245/S10434-011-2058-8) (2013) (8)
Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and Neck (2020) (7)
Patient-Oriented Performance Measures (1984) (7)
Justifying the choice of endpoints for clinical trials. (2013) (7)
Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer. (1987) (7)
Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma (2016) (7)
A Method for Evaluating the Impact of Individual Haplotypes on Disease Incidence in Molecular Epidemiology Studies (2004) (7)
A Case‐Series Study of p53 Nuclear Overexpression in Early‐Stage Stomach Cancer (1995) (7)
Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma (2017) (7)
Interaction of CDKN2A and Sun Exposure in the Etiology of Melanoma in the General Population (2011) (7)
Factors associated with p53 nuclear accumulation in prostatic adenocarcinoma. (1994) (7)
Melanoma molecular subtypes: unifying and paradoxical results. (2010) (6)
Statistical methods in medical research P. Armitage and G. Berry, Blackwell Scientific Publications, Oxford, U.K., 1987. No. of pages: 559. Price £22.50 (1988) (6)
Computed tomography screening and lung cancer outcomes. (2007) (6)
Risk factors and p53 nuclear overexpression in early stage intestinal-type adenocarcinoma of the stomach. (1995) (6)
Testing the incremental predictive accuracy of new markers (2013) (6)
Quality of institutional participation in multicenter trials. (1982) (6)
Mining mutation contexts across the cancer genome to map tumor site of origin (2021) (6)
Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas. (1980) (6)
No association between prediagnosis exercise and survival in patients with high‐risk primary melanoma: A population‐based study (2017) (6)
Alcohol Intake and Cigarette Smoking and Risk of a Contralateral Breast Cancer (2009) (5)
Evaluation of efficient designs for observational epidemiologic studies. (1987) (5)
Evidence for Etiologic Subtypes of Breast Cancer in the Carolina Breast Cancer Study (2019) (5)
Planning controlled clinical trials (1997) (5)
Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts (2021) (5)
1. Cross design synthesis: A new strategy for medical effectiveness research. United States General Accounting Office, (GA0/PEMD‐92‐18), Washington, Dc, 1992. no. of pages: 121. Price: Free/(Available from US General Accounting Office, P.O. Box 6015, Gaithersburg, Md 20877, U.S.A.) (1992) (5)
[Investigating Therapies of Potentially Great Benefit: ECMO]: Comment (1989) (5)
Variation of Serum Prostate-Specific Antigen Levels (2013) (4)
DNA-flow cytometry of head and neck carcinoma: the importance of uniform tissue sampling and tumor sites (2004) (4)
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study (2022) (4)
Using the “Hidden” genome to improve classification of cancer types (2020) (4)
Marketing Drugs Too Early in Testing (2006) (4)
Computed Tomography Screening for Lung Cancer—Reply (2007) (4)
Zero tolerance for acronyms (2017) (4)
Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP) (2007) (3)
Estimation of risks when verification of disease status is obtained in a selected group of subjects. (1984) (3)
Testing clonal relatedness of two tumors from the same patient based on their mutational profiles: update of the Clonality R package (2019) (3)
Association of IRF4 single‐nucleotide polymorphism rs12203592 with melanoma‐specific survival (2020) (3)
The costs of cancer drugs (2020) (3)
Planning controlled clinical trials. Prostatic cancer. (1997) (3)
Re: All-cause mortality in randomized trials of cancer screening. (2002) (3)
Optimized variable selection via repeated data splitting (2020) (3)
Selecting a RDBMS for a multi-disciplinary clinical research database (1992) (2)
Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma. (2020) (2)
Diagnostic Tests, Evaluation of (2005) (2)
RE: "A MULTINOMIAL REGRESSION APPROACH TO MODEL OUTCOME HETEROGENEITY". (2018) (2)
Validity of a method for identifying disease subtypes that are etiologically heterogeneous (2021) (2)
Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma. (2020) (2)
Separate Estimation of Primary and Secondary Cancer Preventive Impact: Analysis of a Case-Control Study of Skin Self-Examination and Melanoma (1996) (2)
Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma (2021) (2)
Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data (2020) (2)
Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma (2021) (2)
Two cheers for P-values? by S Senn (2001) (2)
Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer. (2022) (2)
DNA Damage and Repair Capacity in Lung Cancer Patients: Prediction of Multiple Primary Tumors (2015) (2)
Comment on “The Predictive Capacity of Personal Genome Sequencing” (2012) (2)
RESPONSE: Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance (2003) (1)
Risk factor analysis of screening data. (1987) (1)
In Defense of P Values (2020) (1)
Comment on: On the use of familial aggregation in population-based case probands for calculating penetrance. Authors' reply (2003) (1)
Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions (2012) (1)
Resurrecting treatment histories of dead patients. Authors' reply (2005) (1)
The first international workshop on the role and impact of mathematics in medicine: A collective account (2011) (1)
Expedited approval programs at the Food and Drug Administration (2018) (1)
Estimating the Empirical Lorenz Curve in the Presence of Error (2005) (1)
Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations (2021) (1)
Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study (2021) (1)
Adaptive and Dynamic Methods of Treatment Assignment (2005) (1)
Cancer, genes, and the environment. (2000) (1)
The Interaction of Radiation, the Atm Gene and Breast Cancer (2006) (1)
Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study (2021) (1)
An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients (2019) (1)
Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation (2022) (1)
The participation of community hospitals in cancer clinical trials: results and impact of the Eastern Cooperative Oncology Group Program. (1983) (1)
Patterns and sources of information about family melanoma risk among melanoma survivors. (2016) (0)
Cancer in the Elderly: Clinical and Biologic Considerations (1985) (0)
Diagnostic Tests, Multiple† (2014) (0)
Decreasing tumor size explains some improvement in survival from localized breast cancer. (2004) (0)
Abstract CT118: Efficient basket trial designs (2016) (0)
Reflections on Publication Criteria for Genetic (2005) (0)
Genetic variation at MC1R, GSTT1, and GSTM1 may increase risk for melanoma (1999) (0)
BAYES THEOREM AND CONDITIONAL NONINDEPENDENCE OF DATE IN MEDICAL DIAGNOSIS (1994) (0)
523 ANRIL inherited variants associated with primary melanoma TIL grade (2021) (0)
Identification of patients at increased risk of amelanotic melanoma (2010) (0)
Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based Genes, Environment, and Melanoma (GEM) Study. (2018) (0)
Abstract Fifteenth Annual Meeting of the Society for Clinical Trials The Westin Galleria Hotel, Houston, Texas May 8–11, 1994108P Development of a user's manual for a general purpose clinical research database (1994) (0)
11P Transferring crucial research data from existing systems to an integrated system— The design and technique perspective (1994) (0)
Proceedings of the third international molecular pathological epidemiology (MPE) meeting (2017) (0)
Human genes differ by their UV sensitivity estimated through analysis of UV‐induced silent mutations in melanoma (2020) (0)
Predicting Cancer Risk from Germline Whole-exome Sequencing Data Using a Novel Context-based Variant Aggregation Approach (2023) (0)
Phenotypic characteristics in relationship to BRAF and NRAS mutations in melanoma (2006) (0)
Abstract P3-07-01: Clonal Relatedness between Lobular Carcinoma In Situ and Synchronous Malignant Lesions: Analysis of Fresh Frozen Tissue Using SNP Array (2010) (0)
Diagnostic Tests, Evaluation of† (2014) (0)
Targeted therapy in oncology (2007) (0)
Pathway Alterations in Stage II/III Primary Melanoma. (2023) (0)
Clonal relationships between lobular carcinoma in situ and other breast malignancies (2016) (0)
Constitutive genetic instability in patients with multiple, primary non-small cell lung cancers (2005) (0)
Adapting an Undergraduate Summer Internship to a Virtual Format: Implementing a Mentored Cancer Research Experience to Meet Rising Demand for Flexible Learning Environments (2022) (0)
Topical Hidden Genome: Discovering Latent Cancer Mutational Topics using a Bayesian Multilevel Context-learning Approach (2022) (0)
Risk Prediction and Etiologic Heterogeneity (2014) (0)
Some Issues in the Comparison of Diagnostic Tests from a Paired Experiment (1997) (0)
High-Dose Chemotherapy III Breast Cancer (1991) (0)
Clinical trials in Russia (2021) (0)
49A Development of a centralized data management and computing resource at a large academic clinical research center (1994) (0)
Editorial (2019) (0)
Dataset for: A comparison of statistical methods for the study of etiologic heterogeneity (2017) (0)
Editorial transition (2001) (0)
Expansion of an institutional quality control program at a comprehensive cancer center (1998) (0)
Erratum to: Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas (2012) (0)
Editorial: Quality of cancer clinical trials (1990) (0)
Adjuvant C hemotherapy U se f or M edicare B eneficiaries With S tage I I C olon C ancer (2002) (0)
P72 Hands on user training following a clinical research database upgrade (1997) (0)
Author reply (0)
PAX3 Is Extensively Expressed in Benign and Malignant Tissues of the Melanocytic Lineage in Humans (2010) (0)
526 Functional, inherited vitamin D-binding protein variants associated with mortality among melanoma patients (2021) (0)
09P Establishing a training program for new data managers in clinical research (1994) (0)
13P Transferring crucial research data from existing systems to an integrated system— The data manager's perspective (1994) (0)
P21 Quality control in clinical trials: Protocol compliance auditing (1995) (0)
MC1R variants in childhood and adolescent melanoma: A pooled-analysis from a large worldwide multicenter cohort of patients (2019) (0)
Abstract Fifteenth Annual Meeting of the Society for Clinical Trials The Westin Galleria Hotel, Houston, Texas May 8–11, 199417P Design of a comprehensive security system for a clinical research database (1994) (0)
Statistical Evaluation of Evidence for Clonal Allelic Alterations in array-CGH Experiments (2007) (0)
O-054 Genetic instability, response to DNA damage, and repair capacity in individuals with multiple primary non-small cell lung cancers (2005) (0)
Abstract B127: Family history of breast cancer and risk of contralateral breast cancer (2010) (0)
Resurrecting Treatment Histories of Dead Patients—Reply (2005) (0)
Who G ets A djuvant T reatment f or S tage I I a nd I II R ectal Cancer? I nsight F rom S urveillance, E pidemiology, a nd E nd Results-Medicare (2001) (0)
P59 Design and implementation of a clinical research database in client/server architecture (1997) (0)
A Hybrid Bayesian Laplacian Approach for Generalized Linear Mixed Models (2011) (0)
Computed tomography screening for lung cancer. Authors' reply (2007) (0)
Editorial: Clinical trial design in the era of COVID-19 (2020) (0)
P54 Educating data managers — What needs to be done? (1993) (0)
Methylation of nonessential genes in cutaneous melanoma – Rule Out hypothesis (2023) (0)
658Familial aggregation of melanoma by anatomic site of occurrence (2021) (0)
What ’ s in a Name ? : Heat Shock Protein 27 and Keratinocyte Differentiation (2010) (0)
Diagnostic Tests, Multiple (2005) (0)
Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study (2021) (0)
Quality of cancer clinical trials. (1990) (0)
2018 Peer Reviewers (2019) (0)
Discussion remarks on meta-analysis (1998) (0)
The development of data collection tools to assist in protocol management (1992) (0)
The toxicity of TBI in active cell: A titration technique (1979) (0)
Evolving challenges in clinical trials design (2022) (0)
Proceedings of the second international molecular pathological epidemiology (MPE) meeting (2015) (0)
48A Data management training through worksheets and games (1994) (0)
Year Paper A Hybrid Bayesian Laplacian Approach for Generalized Linear Mixed Models (2017) (0)
A Metastasis or a Second Independent Cancer ? Evaluating the Clonal Origin of Tumors Using Array-CGH Data (2017) (0)
20 Implementing a centralized protocol-patient accrual system — short and long term benefits (1997) (0)
ociations of Cumulative Sun Exposure and Phenotypic B & P racteristics with Histologic Solar Elastosis (2010) (0)
Blocking and randomization to improve molecular biomarker discovery. (2014) (0)
Abstract Fifteenth Annual Meeting of the Society for Clinical Trials The Westin Galleria Hotel, Houston, Texas May 8–11, 199426P Form and data classification in a relational database (1994) (0)
71P Incorporating quality of life surveys into a relational database management system—A general design for handling questionnaire data (1994) (0)
P55 Designing a registration system for the clinical research database system (1993) (0)
A07 Data management workload assessment for medical oncology (1993) (0)
Comments and response on the USPSTF recommendation on screening for breast cancer. (2010) (0)
Comparison of the response and toxicity of total body irradiation vs chlorambucil and prednisone for remission induction of chronic lymphocytic leukemia (active) an ECOG study (1980) (0)
P94 Establishing a system for prospective registration of human subjects participating in research studies at a comprehensive cancer center (1997) (0)
Subsampling based variable selection for generalized linear models. (2023) (0)
Response to discussion (1990) (0)
Disenrollment from Medicare managed care: Does a cancer diagnosis make a difference? (2008) (0)
303 OCCUPATIONAL EXPOSURES, SMOKING, AND RISK OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER IN WESTERN NEW YORK (1995) (0)
Abstract 1016: Variants in autophagy related genes and clinical characteristics in melanoma: a population-based study (2016) (0)
922 CT and MRI staging of malignant pleural mesothelioma: Correlation with surgical/pathologic results (1997) (0)
Abstract A035: Subtype conversion and misclassification of ipsilateral second breast cancer (2022) (0)
P64 An optimal network access in a patient registration system (1997) (0)
Alcohol consumption and breast cancer. (1983) (0)
An EM algorithm to improve the estimation of the probability of clonal relatedness of pairs of tumors in cancer patients (2019) (0)
Erythropoietin improves quality of life—a response (2002) (0)
Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma (1999) (0)

This paper list is powered by the following services:

Other Resources About Colin Begg

en.wikipedia.org

What Schools Are Affiliated With Colin Begg ?

Colin Begg is affiliated with the following schools: